Enveric Biosciences, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $1.0M | $14.8M | $1.8M |
| Jun 2017 | $1.3M | $13.6M | $1.0M |
| Sep 2017 | $1.6M | $12.2M | $844.1K |
| Dec 2017 | $1.1M | $19.4M | $4.9M |
| Mar 2018 | $1.0M | $19.2M | $1.8M |
| Jun 2018 | $926.9K | $18.3M | $915.1K |
| Sep 2018 | $1.7K | $30.1M | $2.1M |
| Dec 2018 | $0 | $-65.5K | $1.4M |
| Mar 2019 | — | $11.2M | $1.7M |
| Jun 2019 | — | $10.9M | $1.6M |
| Sep 2019 | — | $13.2M | $499.7K |
| Dec 2019 | $740.3K | $-1.8M | $431.4K |
| Mar 2020 | — | $-2.7M | $1.3M |
| Jun 2020 | — | $-3.5M | $2.1M |
| Sep 2020 | — | $-3.6M | $2.8M |
| Dec 2020 | — | $3.4M | $1.6M |
| Mar 2021 | — | $19.0M | — |
| Jun 2021 | — | $18.8M | — |
| Sep 2021 | — | $55.4M | — |
| Dec 2021 | — | $22.3M | — |
| Mar 2022 | — | $24.4M | — |
| Jun 2022 | — | $22.0M | — |
| Sep 2022 | — | $22.8M | — |
| Dec 2022 | — | $14.7M | — |
| Mar 2023 | — | $10.4M | — |
| Jun 2023 | — | $4.9M | — |
| Sep 2023 | — | $2.4M | — |
| Dec 2023 | — | $2.0M | — |
| Mar 2024 | — | $6.5M | — |
| Jun 2024 | — | $5.4M | — |
| Sep 2024 | — | $4.0M | — |
| Dec 2024 | — | $1.6M | — |
| Mar 2025 | — | $3.9M | — |
| Jun 2025 | — | $2.2M | — |
| Sep 2025 | — | $3.5M | — |
| Dec 2025 | — | $4.2M | — |
| Mar 2026 | — | $5.1M | — |
| Jun 2026 | — | $8.1M | — |